@heavyphil

Dr Perloe’s published bio indicates he initially (early 2020) did Tulsa Pro after a 3T mpMRI indicated a PIRADS 0.90 cm lesion and a biopsy indicated some 3+4 and some 4+3 cores.

His PSA dropped from 3.9 to 0.40 three months after Tulsa Pro.

He had germline genetic screening, which was negative and Prolaris testing which was on the border between intermediate and aggressive.

Soon after his Tulsa Pro treatment he signed up
for UCLA’s PSMA Ga68 PET scan clinical trial (also in 2020) which showed extension to the left seminal vesicle.

In retrospect he recommends doing a PSMA PET scan prior to undergoing Tulsa Pro, if one is considering that treatment.

Because his PCa was determined to be already outside the prostate he says he’d now would opt for the Oncotype DX GPS, FoundationOne CDx or Guardant360 CDx, instead of Prolaris.

After receiving his PMSA PET result, he completed 5 Viewray MRIdian SBRT treatments at UCLA.

He was offered either no ADT, or ADT with GNRH-agonist, or GNRH-a plus Zytiga and prednisone.

Telemedicine allowed him to get opinions from 4 different medical oncologists from different centers of excellence.

He ultimately decided to proceed with 6 months of ADT+Zytiga+prednisone with careful follow up.

As far as I know, at 75 years old, he’s doing well managing his locally advanced PCa.